drugset / Trial / NCT01731951
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
RandomizedParallel-groupOpen-labelTreatment
Summary
This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2012-10-29
- Primary completion
- 2018-05-24
- Completion
- 2018-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imetelstat | Oligonucleotide (other) | 7.5 mg/kg | Intravenous |
| Subject | Imetelstat | Oligonucleotide (other) | 9.4 mg/kg | Intravenous |